Benyo Tech Secures RMB 200 Million in Series A and A+ Funding to Accelerate Intelligent Automation Transformation in Life Sciences

Recently, BIOYOND Robotics, a company dedicated to accelerating the intelligent automation transformation in the life sciences sector, announced that it has successively completed two rounds of financing, Series A and Series A+, totaling approximately RMB 200 million. Among them,The Series A round was led by a well-known industrial fund. The Series A+ round was co-led by Boyuan Capital and Lilly Asia Ventures (LAV), with follow-on investment from CICC Qide Fund under CICC Capital. Existing shareholders, including Qiming Venture Partners, Sequoia China Seed Fund, and Zhangke Herun Fund, continued to participate in the financing.。

It is reported that Sequoia China Seed Fund participated in the incubation of BIOYOND Robotics at its inception and provided angel-round financing in early 2021. In the same year, the company secured Pre-A round financing led by Qiming Venture Partners, with follow-on investments from Sequoia China Seed Fund and Zhangke Herun Fund.

To date, less than two years after its establishment, BIOYOND Robotics has completed four rounds of financing, raising a total of approximately RMB 300 million. The funds raised have been continuously invested in product research and development, manufacturing, platform construction, and market expansion, accelerating the provision of more user-friendly and efficient automated products and solutions for various fields, including pharmaceuticals, clinical diagnostics, scientific research, and materials and chemical engineering.

Customer Project Delivery: Real-World Implementation

BIOYOND Robotics is a technology-driven innovative tech company headquartered in Zhangjiang Science City, Shanghai, with over 100 employees. R&D personnel account for as high as 70% of its workforce, hailing from renowned domestic and international institutions such as Peking University, The University of Hong Kong, Zhejiang University, Shanghai Jiao Tong University, University of Science and Technology of China, Wuhan University, Rochester Institute of Technology, RWTH Aachen University, and Arizona State University.

The founding team of the company previously held senior executive positions at Fortune 500 companies in the robotics and life sciences sectors, boasting a strong background in scientific research and extensive experience in product development. Tang Yang, Founder and CEO of BIOYOND Robotics, is a prime representative of this group. After graduating in 2004, he joined the Robotics Division of ABB, one of the “Big Four” global robotics manufacturers. He subsequently served as President of ABB Robotics’ China R&D Center and President of ABB Robotics’ Consumer Products and Service Robotics Business Unit in China.

"From automobiles and components to 3C electronics, and then to new energy and logistics, Tang Yang, who is well-versed in the development trends of the robotics industry, has now set his sights on the life sciences sector."The life sciences sector is undergoing a profound technological transformation, and we believe that automation technology is one of the core driving forces leading and accelerating this change.“said Tang Yang.

Currently, BIOYOND Robotics hasThree Core Technology Platforms: Robotics, Automation, Data & CloudTo meet the needs of users in the life sciences industry, the company has developed an automated system featuring flexible configuration and rapid deployment, built upon its fully self-developed high-performance flexible robots, a rich array of instrument modules, and user-friendly intelligent software. Furthermore, leveraging advanced artificial intelligence and computational engines, the system enables massive data processing, providing reliable scientific analysis and decision-making support for R&D and production personnel.

Leveraging its three core technology platforms, the company serves over 100 renowned enterprises in the life sciences sector, with its products and solutions widely applied inSmall-molecule drugs, biologics, cell and gene therapies, traditional Chinese medicine, synthetic biology, omics research, clinical diagnostics, and materials scienceand other fields.

From top-tier investment firms to leading enterprises in the life sciences industry, stakeholders are increasingly increasing their investments in BIOYOND Robotics. This trend not only affirms the company’s strength and value but also represents a strategic bet on China’s cross-disciplinary innovation in automation, artificial intelligence, and life sciences—a field poised to lead the future. Through strong multi-party collaborations, these entities are jointly driving the intelligent automation revolution in the life sciences sector, leveraging technological power to improve human health.

Guo Shanshan, Partner at Sequoia China“The present moment is the optimal time to leverage advanced technological means to accelerate the translation of innovative achievements in fields such as biotechnology and new materials. BIOYOND Robotics boasts an industry-leading, experienced interdisciplinary team spanning robotics, life sciences, digital intelligence, and automation. We are committed to achieving comprehensive development across industries including biotechnology and pharmaceuticals, clinical diagnostics, and materials science through automated, digitalized, reproducible, and traceable approaches. We look forward to BIOYOND Robotics developing more products and solutions that meet market demands, bringing new breakthroughs to the field of intelligent automation in life sciences.”

Dr. Kan Chen, Partner at Qiming Venture PartnersHe stated, “Traditional manual experimental methods are time-consuming and labor-intensive, and pose challenges in terms of reproducibility, data traceability, and safety. Laboratory automation will transform this R&D paradigm by freeing scientists from tedious experimental procedures, allowing them to devote more time to creative work. Furthermore, with the widespread adoption of AI in the biopharmaceutical industry, the importance of big data has become self-evident; automation is a powerful tool for generating large volumes of structured, high-dimensional data. BIOYOND Robotics has assembled an efficient interdisciplinary R&D team spanning robotics, automation, software, and laboratory sciences. We have great confidence in Mr. Tang’s team and believe that BIOYOND Robotics will bring more transformative impact to the biopharmaceutical industry.”

Dr. Yang Tao, Project Leader at Boyuan Capitalstated, “We are delighted to lead the A+ financing round for BIOYOND Robotics. In recent years, we have witnessed the immense potential demonstrated by the convergence of multidisciplinary fields, such as automation, within the life sciences sector. We have also recognized the significant opportunities arising from the paradigm shift in life sciences from traditional experimental science to data science. We firmly believe in the foundational role that automation plays in optimizing R&D workflows, enhancing the standardization of experimental data, and reducing costs while improving efficiency in production. The BIOYOND team boasts top-tier capabilities in China in software and collaborative robot R&D, as well as in the implementation of automated system solutions, and has established extensive collaborations with multiple leading enterprises both domestically and internationally. We look forward to BIOYOND Robotics helping to upgrade China’s life sciences automation industry and building a leading brand in this field.”

Zou Jieyu, Partner at Lilly Asia VenturesIt was stated that, compared with traditional manual operations, laboratory automation products can effectively optimize workflows, significantly improve efficiency and accuracy, and reduce contamination risks for both laboratories and samples. In the post-pandemic era, the further rise in labor costs has also driven enterprises to favor automated solutions that are efficient, stable, and offer greater long-term cost-effectiveness. The BIOYOND Robotics team has accumulated many years of R&D and management experience in the fields of automation and life sciences. Leveraging the superior performance of its products, a deep understanding of customer needs, as well as first-class product design and project engineering capabilities, the company has gained high recognition from leading clients. “We are honored to partner with BIOYOND Robotics and support the company’s rapid development under the leadership of its outstanding founding team.”

Gu Jiefeng, Deputy General Manager of Zhangke Herun Fund“The domestic life sciences industry has demonstrated substantial genuine demand for automation and intelligence across experimental workflows in multiple niche segments, revealing robust market potential. Herun Fund has long accompanied BIOYOND Robotics throughout its growth and development, witnessing the company’s continuous expansion, enrichment, and deepening of its product pipeline and technology platforms, as well as the significant progress achieved by its team through case-by-case refinement. Herun is honored to have participated in this series of financing rounds and looks forward to BIOYOND Robotics’ continued expansion of application boundaries, delivering more outstanding products that address critical market pain points.”

Liang Ying, Managing Director of CICC Capital and Head of the CICC Qide Fund“He stated, ‘As China’s population aging deepens, labor shortages have become an unavoidable reality, particularly for high-quality laboratory technical talent. Therefore, artificial intelligence and automation will be crucial pathways to enhancing the efficiency of life science experiments. Leveraging its team’s successful collaboration experience with major clients and its robust, multidisciplinary technological reserves, BIOYOND Robotics has established significant competitive advantages in this field and formed a strong ecosystem with our portfolio companies. We wish BIOYOND Robotics continued success and rapid growth in the field of life science automation!’”

Sequoia China Seed Fund is a specialized investment fund under Sequoia China, focusing on angel and seed-stage investments. Since its establishment as a separate entity in 2018, the fund’s assets under management have exceeded RMB 10 billion. It strategically targets early-stage structural innovation opportunities in technology, consumer, and healthcare sectors. The fund has invested in more than 300 early-stage startups, several of which have grown into unicorns with valuations exceeding USD 1 billion.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages 11 U.S. dollar funds and 7 RMB funds, with total assets under management reaching $9.4 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.

Boyuan Capital was established in 2017 as a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, Boyuan Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, Boyuan Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained committed to an entrepreneur-centric approach, providing sustained support and active empowerment to exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

Lilly Asia Ventures (LAV) is a premier venture capital fund dedicated to investing in the life sciences and healthcare sectors. Headquartered in Shanghai, China, with offices in Hong Kong, China, and Silicon Valley, USA, our long-term vision is to build exceptional companies that overcome diseases and improve human health through breakthrough products, and to serve as a trusted partner for outstanding entrepreneurs seeking smart capital.

Zhangke Herun Fund is managed by Zhangjiang Sci-Tech Investment, a wholly-owned subsidiary of Zhangjiang Group, with the Pudong Science and Technology Innovation Fund of Funds serving as its cornerstone investor. The fund focuses primarily on innovative drugs, medical devices, and healthcare services. As Zhangjiang Group’s biomedical investment platform, Zhangke Herun Fund leverages Zhangjiang’s industrial ecosystem and park resources to support the robust growth of high-quality, high-potential enterprises in the life and health sectors.

CICC Capital is the private equity investment fund operating platform of China International Capital Corporation Limited (“CICC”), managing CICC’s onshore and offshore private equity investment fund businesses, and has developed into one of China’s leading private equity investment management institutions. Currently, the types of funds under management include RMB corporate equity investment funds, funds of funds, real estate funds, infrastructure funds, and USD corporate equity investment funds.

(The above rankings are not in any particular order.)

Headquartered in Shanghai Zhangjiang Science City, BIOYOND Robotics was founded by a team from Fortune 500 companies in the robotics and life sciences sectors, boasting profound scientific research backgrounds and extensive product development experience. Since its establishment, the company has secured hundreds of millions of yuan in strategic investments across multiple rounds from top-tier institutions and currently serves over one hundred renowned enterprises in the life sciences industry.

BIOYOND Robotics is dedicated to accelerating the intelligent automation transformation in the life sciences sector. By leveraging leading-edge robotics, automation, and artificial intelligence technologies, we provide more user-friendly and efficient automated products and solutions for diverse fields, including small-molecule drugs, biologics, cell and gene therapies, traditional Chinese medicine, synthetic biology, omics research, clinical diagnostics, and materials science.